Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Fibrocell Science Inc.
Headquarters: Exton, PA, United States of America
Website: N/A
Year Founded: 1995
Status: Acquired
BioCentury | Jun 14, 2022
Management Tracks
McCracken named CEO at Evonetix
Plus Pirzkall becomes CMO at Asher, and updates from Domain, Syndax,
BioCentury | Sep 17, 2019
Company News
Sept. 13 Company Quick Takes: FDA issues warning on CDK4/6 drugs; plus Castle Creek to buy Fibrocell and Eidos rebuffs BridgeBio
BioCentury | Aug 23, 2019
Company News
Management tracks: Erasca, Frequency, PerkinElmer, CytomX, Infinity and more
BioCentury | Apr 19, 2019
Company News
Castle Creek gets U.S. rights to market Fibrocell's skin disease cell therapy
BioCentury | Mar 22, 2018
Translation in Brief
Switching scleroderma
How Fibrocell is controlling collagenase to treat localized scleroderma
BioCentury | Nov 30, 2017
Clinical News
Fibrocell reports Phase I/II data for FCX-007 in epidermolysis bullosa
BioCentury | Nov 9, 2017
Preclinical News
LAMB3 gene therapy successfully treats epidermolysis bullosa
BioCentury | Jun 15, 2017
Clinical News
Fibrocell's gene therapy gets rare pediatric disease designation for localized scleroderma
BioCentury | Sep 12, 2016
Financial News
Fibrocell completes private placement of convertible notes and warrants
Items per page:
1 - 10 of 72